Authors
Loading...
Biomarker study reveals a seven-gene panel for monitoring minimal residual disease in pediatric acute myeloid leukemia, suggesting potential therapeutic targets for immunotherapy.
Steinbach et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: